microRNA-660 Enhances Cisplatin Sensitivity via Decreasing SATB2 Expression in Lung Adenocarcinoma

Increasing evidence suggests that microRNAs’ (miRNAs) abnormal expression is one of the main factors of chemotherapy resistance in various cancers. However, the role of miRNAs in lung adenocarcinoma (LUAD) resistance to cisplatin is still unclear. In this study, we analyzed a microarray dataset to investigate miRNAs related to cisplatin resistance in LUAD. The expression of miRNAs in LUAD tissues and cell lines was detected using real-time quantitative polymerase chain reaction (RT-qPCR). Special AT-Rich Sequence-Binding Protein 2 (SATB2) in LUAD cell lines was detected using RT-qPCR and Western blot. Cell proliferation was measured by CCK8 and colony formation assays, while cell cycle and apoptosis were measured by flow cytometry. A dual-luciferase reporter assay was performed to confirm that SATB2 is a target gene ofmicroRNA-660(miR-660). We showed that the expression ofmiR-660was not only decreased in LUAD cells and tissues but also further decreased in the cisplatin-resistant A549 cell line. The overexpression ofmiR-660increased cisplatin sensitivity in LUAD cells. In addition, we identified SATB2 as a direct target gene ofmiR-660. We also revealed thatmiR-660increased cisplatin sensitivity in LUAD cells via targeting SATB2. In conclusion,miR-660/SATB2 axis is a key regulator of cisplatin resistance in LUAD.Keywords:miR-660;SATB2;cisplatin sensitivity;lung adenocarcinoma

文章引用产品列表